GLP-1-derived nonapeptide GLP-1 (28–36) amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice
E Tomas, JA Wood, V Stanojevic, JF Habener - Regulatory peptides, 2011 - Elsevier
Background The metabolic syndrome is an obesity-associated disease manifested as
severe insulin resistance, hyperlipidemia, hepatic steatosis, and diabetes. Previously we
proposed that a nonapeptide, FIAWLVKGRamide, GLP-1 (28–36) amide, derived from the
gluco-incretin hormone, glucagon-like peptide-1 (GLP-1), might have insulin-like actions.
Recently, we reported that the nonapeptide appears to enter hepatocytes, target to
mitochondria, and suppress glucose production and reactive oxygen species. Therefore, the …
severe insulin resistance, hyperlipidemia, hepatic steatosis, and diabetes. Previously we
proposed that a nonapeptide, FIAWLVKGRamide, GLP-1 (28–36) amide, derived from the
gluco-incretin hormone, glucagon-like peptide-1 (GLP-1), might have insulin-like actions.
Recently, we reported that the nonapeptide appears to enter hepatocytes, target to
mitochondria, and suppress glucose production and reactive oxygen species. Therefore, the …